Life science investment company Ally Bridge Group said on Thursday that it has supported and led an over-subscribed USD65m financing of Pulmonx Corporation.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx Corporation is a provider of diagnostic and therapeutic pulmonary device technologies, with its key product approved and marketed in the US, Europe, Australia, and Asia, including China.
Pulmonx's key product, Zephyr Valve, is the first minimally-invasive device approved by the US FDA for treating patients with severe emphysema, a progressive and life-threatening form of COPD. The Zephyr Valve treatment is included in emphysema treatment guidelines issued by leading health organisations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK's National Institute for Health and Care Excellence (NICE), Ally Bridge Group said.
The company's investment in Pulmonx follows new or follow-on investments in Axonics (NASDAQ:AXNX), Vapotherm (NASDAQ:VAPO), OrthoPediatrics (NASDAQ:KIDS), Shockwave Medical (NASDAQ:SWAV) and Silk Road Medical (NASDAQ:SILK).
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid